Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

NCT06253520 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

210

Enrollment

NIH

Sponsor class

Conditions

Metastatic Solid Cancers
Colorectal Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Gastrointestinal Cancer
Ovarian Cancer
Genitourinary Cancer

Interventions

DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: KRAS TCR-Transduced PBL
BIOLOGICAL: GRT-C903/GRT-R904

Sponsor

National Cancer Institute (NCI)